Convertible Securities Holders grant 45-day extension to complete Tender Exchange     Elto Pharma recruiting seasoned management to lead “Go-Public” transaction     Management attending RESI JPM 2018 on Tuesday, January 9, 2018 SAN FRANCISCO, Jan. 09, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire — Amarantus Bioscience Holdings, Inc. (USOTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that a controlling majority of its secured creditors and convertible preferred securities holders have agreed to a 45-day extension to complete the Tender Exchange of convertible securities under the Forbearance and Capital Restructuring Agreements […]